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Abstract
 
The serine/threonine kinase protein kinase B (PKB)/Akt mediates cell survival in a variety of
systems. We have generated transgenic mice expressing a constitutively active form of PKB
(gag-PKB) to examine the effects of PKB activity on T lymphocyte survival. Thymocytes and
mature T cells overexpressing gag-PKB displayed increased active PKB, enhanced viability in
culture, and resistance to a variety of apoptotic stimuli. PKB activity prolonged the survival of
CD4
 
1
 
CD8
 
1
 
 double positive (DP) thymocytes in fetal thymic organ culture, but was unable to
prevent antigen-induced clonal deletion of thymocytes expressing the major histocompatibility
complex class I–restricted P14 T cell receptor (TCR). In mature T lymphocytes, PKB can be
activated in response to TCR stimulation, and peptide-antigen–specific proliferation is en-
hanced in T cells expressing the gag-PKB transgene. Both thymocytes and T cells overexpress-
ing gag-PKB displayed elevated levels of the antiapoptotic molecule Bcl-X
 
L
 
. In addition, the
activation of peripheral T cells led to enhanced nuclear factor (NF)-
 
k
 
B activation via acceler-
ated degradation of the NF-
 
k
 
B inhibitory protein I
 
k
 
B
 
a
 
. Our data highlight a physiological
role for PKB in promoting survival of DP thymocytes and mature T cells, and provide evi-
dence for the direct association of three major survival molecules (PKB, Bcl-X
 
L
 
, and NF-
 
k
 
B)
in vivo in T lymphocytes.
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Introduction
 
The induction of survival versus apoptosis is a central issue
during T cell development and activation. The differential
regulation of thymocyte survival versus death through
TCR-mediated selection signals plays a key role in estab-
lishing a functional mature T cell repertoire (1). In mature
T cells, several studies have demonstrated that signals from
MHC molecules are required for the survival of resting T
cells (2–4). In addition, the induction of apoptosis is strictly
regulated after antigenic triggering (5). However, during T
cell activation, the T cell costimulatory molecule CD28 is
believed to contribute to survival signals (6–8).
Several molecules have been identified that play key roles
in regulating apoptosis in T cells (9). Important advances in
understanding T cell apoptosis have come through the
study of Bcl-2 family members. Bcl-2–related proteins
function to promote either cell survival (such as Bcl-2 and
 
Bcl-X
 
L
 
) or cell death (such as Bax and BAD). Several stud-
ies have demonstrated that overexpression of Bcl-2 (10, 11)
or Bcl-X
 
L
 
 (12, 13) in thymocytes confers resistance to
spontaneous apoptosis and apoptosis induced by a variety of
death stimuli. Conversely, overexpression of death-pro-
moting proteins Bax (14) or BAD (15) in thymocytes accel-
erates cell death in response to apoptosis-inducing stimuli.
However, signaling pathways that control expression of
these molecules in T cells are not well understood.
Recent studies have identified an important role for a
phosphatidylinositol 3-kinase (PI3K)
 
1
 
-mediated signaling
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pathway in the suppression of apoptosis. The serine/threo-
nine kinase protein kinase B
 
a
 
 (PKB/Akt), a downstream
target of PI3K activity, is emerging as a key molecule in-
volved in regulating cell survival in a variety of models
(16). Activated PKB has been demonstrated to play a role
in growth factor– and cytokine-mediated survival, and pro-
tects cells from apoptosis induced by a variety of stimuli,
including UV irradiation, c-myc overexpression, Fas-medi-
ated cell death, and matrix detachment (17). PI3K-medi-
ated phosphorylation of phosphatidylinositol functions to
recruit PKB and the protein kinases PDK-1 and PDK-2 to
the plasma membrane, allowing for direct phosphorylation
of PKB by these kinases. Phosphorylation on Thr-308 and
Ser-473 is required for the full activation of PKB-
 
a
 
, which
then dissociates from the plasma membrane and phosphor-
ylates a variety of substrates (18).
The mechanisms by which PKB promotes cell survival
remain controversial, although recent data suggest that
PKB may interact directly with several components of cell
death machinery. PKB has been shown to antagonize the
proapoptotic functions of the Bcl-2–related molecule BAD
(19, 20) and caspase 9 (21) through direct phosphorylation.
Alternatively, PKB may alter gene transcription upon bind-
ing of survival factors through the regulation of transcrip-
tion factors (22–25). PKB is able to inhibit the function of
members of the Forkhead family of transcription factors via
direct phosphorylation, resulting in their nuclear exclusion.
In addition, PKB has recently been implicated as a positive
regulator of nuclear factor (NF)-
 
k
 
B activation in fibroblasts
(26), embryonic kidney cells (27), and Jurkat cells (28).
PKB has been shown to transactivate I
 
k
 
B kinase 
 
a 
 
(IKK
 
a
 
),
which leads to I
 
k
 
B degradation via phosphorylation and
nuclear translocation of NF-
 
k
 
B (26, 27).
Although the role of PKB as a general mediator of cell
survival has been well documented, the function of PKB in
T cells is unknown. To investigate the role of PKB activity
in primary T cells, we generated mice expressing a consti-
tutively active form of PKB (gag-PKB) in the T cell lin-
eage. In this study, we demonstrate that overexpressed, ac-
tive PKB can promote CD4
 
1
 
CD8
 
1
 
 double positive (DP)
thymocyte survival and mature T cell survival. We also
show that PKB can be activated downstream of the TCR
in peripheral T cells and link PKB activation with the NF-
 
k
 
B survival pathway in T cells. Finally, we provide evi-
dence that PKB regulates expression of the antiapoptotic
molecule Bcl-X
 
L
 
. Our results support a model of PKB-medi-
ated survival through the regulation of the antiapoptotic
molecules NF-
 
k
 
B and Bcl-X
 
L
 
 in T cells.
 
Materials and Methods
 
Generation of Transgenic Mice.
 
Construction of the gag-PKB
cDNA has been described previously (29). To target gag-PKB to
the T cell lineage, gag-PKB cDNA was inserted into EcoRI and
SmaI sites of the human CD2 minigene cassette (30). The hCD2-
gag-PKB insert was linearized and microinjected into fertilized
eggs from (CBA/J 
 
3
 
 B6)F
 
2
 
 animals. Two founder lines, 4-1 and
5-4, were backcrossed to C57BL/6J mice for at least three gener-
 
ations before characterization. The presence of the gag-PKB
transgene was detected by Southern blot using an 
 
a
 
-
 
32
 
P–radiola-
beled gag-PKB–specific probe and EcoRI-digested tail DNA
from 3–4-wk-old mice. Alternatively, mice were genotyped via
PCR using tail DNA, sense primer 5
 
9
 
-CCTTGAACCTC-
CTCGTTCGAC-3
 
9
 
, and antisense primer 5
 
9
 
-GATGTACT-
CAC CTCGCTTGTG-3
 
9
 
.
 
Mice.
 
C57BL/6J mice were obtained from The Jackson Lab-
oratory. TCR transgenic mice were generated previously using 
 
a
 
and 
 
b
 
 chains isolated from CTL clone P14, which recognizes the
lymphocytic choriomeningitis virus (LCMV) glycoprotein (pep-
tide p33-41) in the context of H-2D
 
b
 
 (31). Mice homozygous for
the P14 TCR transgene (327 line) were used in timed matings
with heterozygous gag-PKB mice for fetal thymic organ culture
(FTOC). All mice were maintained in a specific pathogen-free
environment at the Ontario Cancer Institute according to institu-
tional guidelines.
 
Cell Preparation.
 
Single cell suspensions of lymphoid organs
were generated by gently pressing organs through sterile wire
mesh. Cells were washed once in cold HBSS and resuspended in
IMDM, supplemented with 10% heat-inactivated FCS (GIBCO
BRL), 50 
 
m
 
M 
 
b
 
-mercaptoethanol, 2 mM glutamine, and 0.1%
penicillin/streptomycin. CD4
 
1
 
 and CD8
 
1
 
 splenic T cells were
isolated via magnetic cell sorting using MACS
 
®
 
 separation col-
umns (Miltenyi Biotec). Splenic preparations were enriched
 
.
 
90% for CD4
 
1
 
 and CD8
 
1
 
 T cells as determined by flow cy-
tometry.
 
Reagents and Antibodies.
 
Dexamethasone and 7-amino-actino-
mycin D (7AAD) were purchased from Sigma-Aldrich. Recom-
binant hCD8-mFasL fusion protein (32) and hamster anti–mouse
CD3 antibody were supplied by Amgen. Purified anti-CD28
(37.51) was purchased from BD PharMingen. The LCMV glyco-
protein peptide p33 (KAVYNFATM) and the adenovirus peptide
AV (SGPSNTPPEI) were synthesized and purified as described
previously (33). The following mAbs were used for flow cytome-
try: PE-conjugated anti–mouse CD4, FITC-conjugated anti-
CD8, biotinylated anti–heat-stable antigen (HSA) (M1/69), bio-
tinylated anti-V
 
a
 
2 (B20.1), and FITC-conjugated anti–Bcl-2
(3F11) (BD PharMingen). Biotinylated antibodies were detected
with streptavidin–Red 670 (GIBCO BRL).
 
Apoptosis Assays.
 
For analysis of spontaneous cell death, thy-
mocytes or magnetically sorted CD4
 
1
 
 and CD8
 
1
 
 splenic T cells
were suspended at 10
 
6
 
 cells per ml in IMDM supplemented with
5% heat-inactivated FCS, 2 mM 
 
l
 
-glutamine, 50 
 
m
 
M 
 
b
 
-mercap-
toethanol, and antibiotics, and cultured in 24-well tissue culture
plates. Samples were harvested at various time points, and cell vi-
ability was determined by trypan blue exclusion. CD4 versus
CD8 thymocyte profiles were assessed over time by flow cytom-
etry. Thymocytes were stained with PE-conjugated anti-CD4,
FITC-conjugated anti-CD8, 7AAD, and CD4 versus CD8 thy-
mocyte profiles were determined for 7AAD
 
2
 
 populations (34).
For analysis of apoptotic cell death, thymocytes and sorted T
cells were plated as above and subjected to apoptotic treatment as
indicated. Cell viability was determined by trypan blue exclusion
or by FACS
 
®
 
 analysis using Annexin V-FITC and propidium io-
dide (PI) staining according to the manufacturer’s instructions
(R&D Systems).
 
FTOC.
 
Timed matings were established between female
mice homozygous for the P14 transgenic TCR (327 line) and
male mice heterozygous for the gag-PKB transgene, and fetal
thymic lobes were isolated from day 16.5 embryos. PCR analysis
was performed on DNA isolated from individual embryos to de-
tect the presence or absence of the gag-PKB transgene. The fetal 
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thymic lobes were separated and transferred onto 0.8-
 
m
 
M nucleo-
pore polycarbonate filters (Costar) and cultured for 6 d at 37
 
8
 
C,
5% CO
 
2
 
 in complete medium (IMDM supplemented with 10%
heat-inactivated FCS, 2 mM 
 
l
 
-glutamine, 50 
 
m
 
M 
 
b
 
-mercaptoeth-
anol, and antibiotics). In addition, thymic lobes were cultured in
the presence or absence of exogenous p33 peptide (10
 
2
 
6
 
 M). Me-
dia and peptides were changed daily. Thymocytes were harvested
by passing thymic lobes through a nylon mesh, stained with
mAbs at 4
 
8
 
C, and analyzed via flow cytometry.
 
T Cell Proliferation Assays.
 
Splenocytes (5 
 
3
 
 10
 
4
 
) from P14
TCR transgenic or P14 TCR/gag-PKB double transgenic mice
were cultured with 10
 
5
 
 C57BL/6 spleen cells prepulsed with
peptide in triplicate in 96-well flat-bottomed plates. Cultures
were pulsed with 1 
 
m
 
Ci/well [
 
3
 
H]thymidine (Dupont) for the fi-
nal 8 h of culture and harvested onto glass fiber filters. [
 
3
 
H]Thy-
midine uptake was measured using a scintillation counter (Top-
count; Canberra Packard).
 
Western Blot Analysis.
 
Single cell suspensions were lysed by
incubation on ice in Gentle Soft Buffer (10 mM NaCl, 20 mM
Pipes [pH 7.4], 0.5% NP-40, 5 mM EDTA, 5 
 
m
 
g/ml leupeptin,
1 mM benzamidine, 0.5 mM NaF, and 100 
 
m
 
M Na
 
3
 
VO
 
4
 
) for 20
min. Lysates were cleared by centrifugation and supernatants
were normalized for total protein by Bradford assay (Bio-Rad).
Proteins were resolved by 12.5% SDS-PAGE, electroblotted to
polyvinylidene difluoride membrane (Costar), blocked in 5%
Tris-buffered saline, 0.05% Tween 20, and probed with primary
antibodies. Anti-PKB, antiphospho S473 PKB, and anti-I
 
k
 
B
 
a
 
antibodies were purchased from New England Biolabs, Inc.
Mouse monoclonal anti–Bcl-X
 
L
 
 (H-5) and goat polyclonal anti-
BAD (C-20) were from Santa Cruz Biotechnology, Inc. Rabbit
polyclonal anti–Bcl-2 was a gift from Dr. David Andrews (Mc-
Master University, Hamilton, Ontario). Antiactin antibodies
were purchased from Sigma-Aldrich. After incubation with
horseradish peroxidase–conjugated goat anti–rabbit antibody
(Amersham Pharmacia Biotech) or goat anti–mouse antibody
(Santa Cruz Biotechnology, Inc.), bound immunoglobulins were
detected using enhanced chemiluminescence (Amersham Phar-
macia Biotech) according to the manufacturer’s directions.
 
Electrophoretic Mobility Shift Assay.
 
Nuclear extracts were har-
vested according to protocols described previously (35). In brief,
6 
 
3
 
 10
 
6
 
 purified T cells, either untreated or stimulated for 4 h
with various treatments, were washed twice with PBS and resus-
pended in 250 
 
m
 
l of buffer A (10 mM Hepes [pH 7.8], 10 mM
KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM dithiothreitol, and
1 mM PMSF). After incubation on ice for 5 min, NP-40 was
added to a final concentration of 0.6%. After centrifugation, cyto-
plasmic proteins were removed and the pelleted nuclei were re-
suspended in 25 
 
m
 
l buffer C (20 mM Hepes [pH 7.9], 0.4 M
NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol, and 1
mM PMSF). After 30 min agitation at 4
 
8
 
C, the samples were
centrifuged and supernatants, containing nuclear proteins, were
transferred to a fresh vial. Equal amounts of nuclear protein, as
determined using the Bio-Rad protein assay, were incubated
with an end-labeled, double-stranded NF-
 
k
 
B–specific oligonu-
cleotide probe containing two tandemly positioned NF-
 
k
 
B–
binding sites (5
 
9
 
-ATC AGG GAC TTT CCG CTG GGG ACT
TTC CG-3
 
9 
 
and 5
 
9
 
-CGG AAA GTC CCC AGC GGA AAG
TCC CTG AT-3
 
9). The reaction was performed in a total of 20
ml of binding buffer (5 mM Hepes [pH 7.8], 50 mM KCl, 0.5
mM dithiothreitol, 1 mg poly [dI-dC], and 10% glycerol) for 20
min at room temperature. After incubation, samples were frac-
tionated on a 5% polyacrylamide gel and visualized by autora-
diography.
Results
Generation of Transgenic Mice Expressing gag-PKB in Thy-
mocytes and Peripheral T Cells. To study the effect of PKB
on T cell development and peripheral function, we gener-
ated transgenic mice overexpressing a constitutively active
form of PKB (gag-PKB) in T lymphocytes under control
of the CD2 promoter and locus control region (LCR) (30).
The gag-PKB–encoded protein is equivalent to the onco-
genic form of PKB, v-akt, and consists of three parts: an in
frame fusion of the viral gag protein, a 21–amino acid pep-
tide linker derived primarily from the 59 untranslated re-
gion of the endogenous PKB gene locus, and PKB (Fig. 1
A) (36). An NH2-terminal glycine residue of the gag por-
tion of the chimeric protein serves as a site for myristylation
(37, 38). This myristyl group preferentially targets the gag-
PKB fusion protein to the cell membrane where it be-
comes constitutively activated by upstream kinases (39).
Two individual founder lines were established, B6/PKB5-4
and B6/PKB4-1, and the latter was predominantly used in
this study. As the active form of PKB is oncogenic (40),
thymocytes and T cells from mice were screened for evi-
dence of lymphomagenesis via hematoxylin and eosin his-
tological staining or by flow cytometry using Vb-specific
antibodies to detect monoclonal expansion of T lympho-
cytes (data not shown). No evidence of lymphoma was de-
tected in mice up to 5 mo of age. All mice used in this
study were 6–16 wk of age.
gag-PKB mRNA expression was measured by reverse
transcription (RT)-PCR on total cellular RNA prepared
from LNs of transgenic mice or littermate controls. Primers
specific for the gag-PKB construct were used to detect spe-
cific expression of the chimeric mRNA and not endoge-
nous PKB mRNA. RT-PCR using RNA from transgenic
(B6/PKB) or nontransgenic (B6) lymphocytes showed ex-
pression of gag-PKB mRNA in transgenic lymphocytes,
and RT minus controls confirmed that there was no con-
taminating genomic DNA in these samples (Fig. 1 B).
Thus, gag-PKB mRNA is produced in lymphocytes of the
transgenic mice.
The expression of gag-PKB and its phosphorylation sta-
tus were determined by Western blot analysis of cell ex-
tracts prepared from thymocytes and peripheral T cells of
gag-PKB transgenic mice. Studies have demonstrated that
the phosphorylation status of PKB, as detected using an an-
tibody specific for PKB phosphorylated at Ser-473, corre-
lates with its kinase activity in vitro (41). Lysates from the
thymus, LN, and purified peripheral T cells from nontrans-
genic animals (B6) and two transgenic founder lines (B6/
PKB5-4 and B6/PKB4-1, respectively) were probed with
anti-PKB or anti–P-S473 PKB antibodies (Fig. 1 C). PKB
levels were elevated in the T cells of mice expressing the
gag-PKB transgene (Fig. 1 C, top). In addition, PKB was
hyperphosphorylated in the transgenic mice compared with
nontransgenic controls (Fig. 1 C, middle). Protein levels of
the p85 regulatory subunit of PI3K, the upstream activator
of PKB, were similar in control and transgenic lines, dem-
onstrating equal protein loading (Fig. 1 C, bottom). Similar1724 PKB Enhances T Cell Survival
results were obtained using whole cell extracts from sple-
nocytes (data not shown). The size of the transgenic pro-
tein detected on the Western blot was much smaller (z55
kD) than the expected gag-PKB fusion protein (z90 kD).
This phenomenon has been observed in transfection studies
using the gag-PKB construct, and was suggested to be due
to an internal translation start site in the gag-PKB mRNA
(42). However, there is evidence that viral gag polyproteins
encode their own cleavage sites during retroviral packaging
events (43). As gag-PKB mRNA is produced, it is possible
that the gag sequence is cleaved from the chimeric protein
after activation, possibly in an autolytic fashion. Overex-
pressed PKB lacking the gag sequence would not be tar-
geted to the plasma membrane, and would not be expected
to exist in a hyperphosphorylated state. Together, these
analyses show that we have established lines of transgenic
mice that express elevated levels of PKB in the T cell lin-
eage, and despite the possible loss of the gag sequence, the
kinase is phosphorylated and activated well above endoge-
nous levels in the T cells of these mice.
PKB Prevents Thymocyte Death in Response to Various Apop-
totic Stimuli. To assay survival of gag-PKB transgenic
thymocytes in response to apoptotic stimuli, thymocytes
were treated with various death agonists and cell viability
was measured over time. Transgenic (B6/PKB5-4 and B6/
PKB4-1) and nontransgenic (B6) thymocytes were treated
with g radiation (250 or 500 rads), the glucocorticoid dexa-
methasone (0.1 or 1 mM), or recombinant hCD8-mFasL
fusion protein (50 or 100 ng/ml), a physiological activator
of Fas (32), and the proportion of viable cells relative to un-
treated controls was determined over time via trypan blue
exclusion (Fig. 2 A). In all conditions, thymocytes express-
ing the gag-PKB transgene showed enhanced viability over
nontransgenic controls. In particular, pronounced differ-
ences in viability (more than two- to threefold) were ob-
served between gag-PKB transgenic and control thy-
mocytes at the higher apoptotic treatments tested (500 rads,
1 mM dexamethasone, and 100 ng/ml hCD8-mFasL; Fig. 2
A). The resistance to Fas-induced killing in transgenic thy-
mocytes was not due to differences in Fas receptor expres-
sion, as the levels of Fas expression were similar in both sets
of thymocytes (data not shown). The transgenic thymocytes
were also resistant to treatment with UV radiation and eto-
poside compared with nontransgenic cells (data not shown).
Similar results were obtained using Annexin V and PI stain-
ing (data not shown), indicators of early and late stages of
programmed cell death, respectively. Together these data
support a role for PKB in regulating T cell survival.
PKB Protects DP Thymocytes from Spontaneous Death In
Vitro. To assess the effect of activated PKB on thymocyte
survival, thymocytes from gag-PKB transgenic (B6/PKB5-4
or B6/PKB4-1) and control littermates (B6) were placed in
culture in IMDM medium supplemented with 5% FCS,
and viability was assessed at various time points by trypan
blue exclusion. Expression of gag-PKB in thymocytes sig-
nificantly improved their rate of survival over time com-
pared with nontransgenic littermate controls (Fig. 2 B). Vi-
ability was similar between the two groups after 2 d in
culture, but gag-PKB thymocytes exhibited a marked in-
crease in survival after this time. Approximately 27 6 3%
of thymocytes from B6/PKB4-1 mice were still viable by
day 8 of culture, compared with 3.8 6 1.7% for control
thymocytes (Fig. 2 B). These results strongly suggest that
PKB can promote extended thymocyte survival in vitro.
Because PKB is expressed, phosphorylated in thymocytes
Figure 1. T cells from transgenic mice express activated PKB. (A) Illus-
tration of the gag-PKB transgene. A 2.3-kb cDNA fragment containing
the coding sequence of gag-PKB was inserted into the EcoRI and SmaI
sites of the human CD2 minigene. The CD2 promoter, polyadenylation
signal (Poly A), and enhancer/locus control region (LCR) are indicated.
The construct was linearized at the KpnI and XbaI sites before microin-
jection. (B) gag-PKB T cells express transgenic gag-PKB mRNA.
DNase-treated total RNA isolated from gag-PKB transgenic (B6/PKB)
and nontransgenic (B6) LN T cells was subjected to RT-PCR using gag-
PKB–specific primers. PCR was performed on the RNA to control for
DNA contamination. In the right lane, gag-PKB cDNA was amplified as
a positive control for the PCR reaction. RT-PCR products were ana-
lyzed on a 1% agarose gel stained with ethidium bromide. (C) Transgenic
gag-PKB T cells display elevated levels of PKB protein and increased lev-
els of PKB phosphorylation. Expression of PKB was assessed in thymus,
LN, and purified CD41 and CD81 T cells from wild-type mice (B6) and
gag-PKB transgenic mice from two independent founder lines (B6/
PKB5-4 and B6/PKB4-1) by Western blot analysis with a polyclonal anti-
PKB antibody. Phosphorylated PKB was detected for the same samples
using a polyclonal antibody specific for PKB phosphorylated at Ser-473.
Lysates from 2 3 106 cells per tissue sample were loaded per lane after
normalization for protein content via the Bradford assay.1725 Jones et al.
(Fig. 1 C), and acts to regulate thymocyte survival (Fig. 2
B), we determined which thymocyte subpopulations dis-
played enhanced survival in the presence of activated PKB.
Thymocytes from transgenic and control mice were cul-
tured for 8 d in IMDM plus 5% FCS, and viable cells from
various time points were assessed for CD4 and CD8 core-
ceptor expression by flow cytometry. There was a gradual
decrease in DP thymocyte survival from 84 to 7% after 8 d
in culture in control thymocytes, whereas gag-PKB trans-
genic DP thymocytes showed a modest decrease from 80
to 61% over the same time period (Fig. 2 C). In terms of
absolute cell numbers, this corresponds to a decrease in
nontransgenic DP thymocytes from 8.4 6 0.15 3 105 to
2.7 6 1.1 3 103, compared with a decrease from 8.0 6 0.2 3
105 to 1.6 6 0.2 3 105 for gag-PKB transgenic DP thy-
mocytes. Thus, overexpression of activated PKB confers
enhanced survival to thymocytes and appears to selectively
regulate the survival of DP thymocytes.
PKB Alters the Survival of DP Thymocytes in FTOC.
The development of a functional T cell repertoire is de-
pendent on the selective survival and programmed death of
thymocytes during positive and negative selection in the
thymus. As the expression of activated PKB appears to en-
hance thymocyte survival in culture and decreases their
sensitivity to apoptosis, we examined whether PKB may
play a role during selection events in the thymus. Flow cy-
tometric analysis of thymocyte subpopulations in adult
mice aged 8–14 wk showed no apparent difference in the
number or proportion of DP, single positive (SP) CD41,
and SP CD81 thymocytes between the gag-PKB trans-
genic mice and nontransgenic littermates (data not shown).
In addition, there appeared to be no significant difference
in thymus cellularity in these animals. These experiments
suggest that expression of gag-PKB does not dramatically
alter thymocyte selection.
To further investigate the effect of PKB on thymocyte
selection, FTOCs were done using the P14 TCR trans-
genic mouse model. P14 TCR transgenic mice express re-
ceptors specific for the LCMV glycoprotein peptide (amino
acids 33–41) presented in the context of H-2Db (31). Ho-
mozygous TCR transgenic mice were bred with mice het-
erozygous for the gag-PKB transgene, and day 16 fetal thy-
mic lobes were harvested and genotyped for the gag-PKB
transgene by PCR. After 6 d in culture, P14 or P14/PKB
fetal thymic lobes were analyzed by three-color flow cy-
tometry with mAbs against CD4, CD8, and Va2 to follow
the transgenic TCR (Fig. 3 A). P14 thymocytes appeared
to display increased positive selection of CD81 thymocytes
compared with P14/PKB thymocytes. However, as shown
in Fig. 3 B, P14 thymic lobes expressing the gag-PKB
transgene showed an increase in cellularity. An average of
45.0 6 4.4 3 104 (n 5 6) thymocytes were recovered from
Figure 2. PKB kinase activity protects thymocytes from various apop-
tosis-inducing stimuli and spontaneous apoptosis in vitro. (A) Transgenic
gag-PKB thymocytes are resistant to g irradiation, dexamethasone, and
anti-Fas–induced apoptosis. Thymocytes from control mice (B6, j) or
mice expressing the gag-PKB transgene (B6/PKB5-4, h; or B6/PKB4-1,
s) were cultured at 106 cells/ml after exposure to g radiation or incuba-
tion in the presence of dexamethasone or recombinant CD8-FasL fusion
protein. Thymocyte viability was determined by trypan blue exclusion at
various time points after apoptotic treatment. Viability is expressed nor-
malized to untreated thymocytes and in triplicate (6SEM). The data are
representative of four independent experiments. (B) PKB activity pro-
motes survival in thymocytes. Thymocytes from transgenic mice (B6/
PKB5-4, h; or B6/PKB4-1, s) or nontransgenic littermate controls (B6,
j) were cultured in 24-well tissue culture plates at 106 cells/ml in IMDM
supplemented with 5% heat-inactivated FCS, 2 mM l-glutamine, and 50
mM b-mercaptoethanol. Cell viability was determined in triplicate by
trypan blue exclusion over 8 d of culture at 378C. The error bars repre-
sent the SEM expressed as cell numbers for each triplicate value. These
data are representative of six independent experiments. (C) PKB activity
selectively protects CD41CD81 DP thymocytes from spontaneous apop-
tosis. Thymocytes from B6/PKB and B6 mice were cultured as in B and
harvested after 0, 4, or 8 d of culture. Cells were stained with FITC-con-
jugated anti-CD8a, PE-conjugated anti-CD4, and 7AAD, and analyzed
via flow cytometry. Viable thymocytes were determined by negative
staining with 7AAD. The mean percentage of DP thymocytes at each
time point is indicated. The presented data are representative of three sep-
arate experiments with two mice per experiment.1726 PKB Enhances T Cell Survival
P14/PKB thymic lobes, compared with 22.0 6 3.8 3 104
(n 5 4) thymocytes for P14 control lobes.
In terms of cellularity, there was no significant difference
in the total number of CD81 cells generated in P14 thymic
lobes with or without expression of the gag-PKB transgene.
An average of 12.6 6 3.0 3 104 (n 5 6) CD81 cells were
recovered from P14/PKB lobes, compared with 9.0 6 1.7 3
104 (n 5 4) cells for P14 lobes (Fig. 3 B). In addition, Va2
staining of the CD81 compartment in P14 versus P14/PKB
thymic lobes suggested that there was no difference in TCR
density associated with the maturation of these CD81 cells
(Fig. 3 A). These data are consistent with the idea that PKB
activity does not significantly alter the positive selection of
thymocytes; rather, active PKB enhances the viability of
CD41 CD81 DP thymocytes in thymic organ culture.
PKB Does Not Prevent Peptide-induced Negative Selection of
Thymocytes in FTOC. To test whether thymocyte nega-
tive selection could be altered by active PKB, P14 and
P14/PKB thymic lobes were cultured in the presence of
1026 M LCMV glycoprotein peptide p33, a concentration
known to induce deletion of P14 TCR transgenic thy-
mocytes in FTOC (44). Negative selection in the P14
TCR transgenic mouse model is defined by a loss of Va21
TCR transgenic thymocytes and an overall decrease in thy-
mus cellularity. 6 d of culture in the presence of p33 pep-
tide resulted in the deletion of CD41CD81 DP and CD81
SP thymocytes expressing the Va2 chain in P14 thymic
lobes regardless of gag-PKB expression (Fig. 4 A). How-
ever, while P14 lobes cultured with 1026 M LCMV glyco-
protein p33 showed a substantial decrease in DP thy-
mocytes, P14/PKB lobes maintained a higher proportion
of DP thymocytes as observed by flow cytometry (23.7 6
6.9%, n 5 4, compared with 53.6 6 9%, n 5 6). Despite
increased numbers, these DP thymocytes did not express
high levels of Va2. It is possible that DP thymocytes
expressing gag-PKB downregulate the transgenic TCR
through a receptor editing process in response to p33, re-
sulting in a Va2lo phenotype. In terms of cellularity, both
P14 and P14/PKB thymic lobes cultured with p33 peptide
showed a decrease in total CD41CD81 DP thymocyte
populations (Fig. 4 B). These data show that negative selec-
tion may not be as efficient in the presence of active PKB,
consistent with the role of PKB in enhancing DP survival.
However, negative selection of TCR transgenic thy-
mocytes is not abrogated in the presence of active PKB.
Active PKB Leads to Increased Expression of Bcl-XL in Thy-
mocytes. Several studies have identified roles for antiapop-
totic molecules of the Bcl-2 family during lymphocyte de-
velopment. Bcl-2 expression is upregulated during positive
selection (45, 46), whereas Bcl-XL is essential for the sur-
vival of DP thymocytes (47, 48). To investigate the role of
PKB in regulating endogenous levels of these molecules in
vivo, thymocytes from B6/PKB and B6 control mice were
lysed and Bcl-2 and Bcl-XL protein levels were examined
by Western blot (Fig. 5). There was no difference in Bcl-2
protein levels in the thymus of these mice as determined by
Western blot (Fig. 5, bottom) or by flow cytometry (data
not shown), suggesting that PKB does not affect Bcl-2 ex-
pression in thymocytes. However, endogenous levels of
Bcl-XL were increased in gag-PKB transgenic mice com-
pared with negative littermate control mice (Fig. 5, top). It
should be noted that Bcl-XL was readily detected in control
thymocytes from nontransgenic animals; however, Bcl-XL
expression in gag-PKB transgenic thymocytes was consid-
erably higher relative to the controls. These results suggest
that PKB influences the level of Bcl-XL protein in develop-
ing thymocytes.
To determine whether RNA levels were increased,
semiquantitative RT-PCR analysis was performed on total
cellular RNA isolated from gag-PKB transgenic or non-
transgenic thymocytes. When normalized to b-actin levels,
Bcl-XL mRNA levels were not significantly different be-
tween gag-PKB thymocytes and nontransgenic controls
(data not shown). These results suggest that PKB does not
regulate Bcl-XL expression in thymocytes by modulating its
transcription. Together, these studies show that active PKB
enhances Bcl-XL levels, which corresponds to the en-
hanced survival of DP thymocytes observed in vitro.
gag-PKB Confers Resistance to Apoptotic Stimuli and Sponta-
neous Apoptosis in Peripheral T Lymphocytes. To investigate
the effects of gag-PKB expression on mature T cell survival,
sorted CD41 and CD81 splenic T cells from gag-PKB
Figure 3. Active PKB en-
hances CD41CD81 DP thy-
mocyte survival in FTOC.
FTOCs from P14 TCR trans-
genic mice with (P14/PKB,
hatched bars) or without (P14,
black bars) the gag-PKB trans-
gene were cultured and stained
with FITC-conjugated anti-
CD8, PE-conjugated anti-CD4,
and biotinylated anti-Va2 or
HSA antibodies. (A) Dot plots
show CD4 and CD8 expression
of thymocytes isolated from P14
and P14/PKB fetal thymic lobes
after 6 d in culture. The percent-
age of cells from each thymocyte subpopulation is indicated. Histograms display the Va2 expression levels of mature (HSAlo) CD81 thymocytes. The
data shown are representative of three independent experiments. (B) Total cell numbers from P14 (n 5 4) and P14/PKB (n 5 6) fetal thymic lobes are
described in A.1727 Jones et al.
transgenic (B6/PKB5-4 or B6/PKB4-1) or nontransgenic an-
imals were exposed to g radiation or treated with various
concentrations of dexamethasone. As measured by viability
dye exclusion, cultured T cells from gag-PKB transgenic
mice showed marked reduction in the kinetics of cell death
relative to nontransgenic littermates in response to dexa-
methasone and g radiation (Fig. 6 A). At 24 h, 53% of
transgenic T cells subjected to 250 rads of g radiation were
apoptotic compared with 77% for control T cells. Likewise,
only 46% of T cells from gag-PKB transgenic mice were
apoptotic in the presence of 0.1 mM dexamethasone com-
pared with 80% of control T cells at 24 h. It should be
noted that expression of gag-PKB confers a 1.5–3-fold in-
crease in survival relative to untreated controls, which is less
than that observed in both Bcl-2 and Bcl-XL transgenic an-
imals (12). It is possible that the differences in apoptosis to
various stimuli may be greater but remain masked due to
the enhanced survival of the untreated gag-PKB transgenic
population. Collectively, these observations indicate that
PKB kinase activity can promote cell survival in peripheral
T cells in response to various apoptotic stimuli.
To address the question of whether PKB activity can
regulate basal T cell survival, we assessed the ability of pe-
ripheral T cells to resist spontaneous apoptosis in culture.
CD41 and CD81 peripheral T cells isolated from the
spleen of gag-PKB transgenic mice displayed increased sur-
vival in culture over time compared with nontransgenic
controls (Fig. 6 B). After 4 d in culture, z31% of B6/PKB
splenic T cells were viable, whereas 7% of nontransgenic
Figure 4. Overexpression of
gag-PKB does not prevent thy-
mocyte negative selection in
FTOC. FTOCs from P14 TCR
transgenic mice with (P14/PKB)
or without (P14) the gag-PKB
transgene were cultured in the
presence or absence of 1026 M
p33 peptide and stained with
FITC-conjugated anti-CD8, PE-
conjugated anti-CD4, and biotin-
ylated anti-Va2 or HSA antibod-
ies. (A) The percentage of cells
from each thymocyte subpopula-
tion is indicated. Histograms dis-
play the Va2 expression levels on
immature (HSAhi) CD41CD81
DP thymocytes and mature
(HSAlo) CD81 thymocytes. (B)
Total thymocyte and CD41CD81 DP thymocyte cell numbers from P14 (black bars) and P14/PKB lobes (hatched bars) after incubation in the presence
or absence of p33 peptide. Values shown represent the mean 6 SEM for four (P14) and six (P14/PKB) thymic lobes. These data are representative of
two independent experiments.
Figure 5. Elevated Bcl-XL protein
levels are detected in gag-PKB trans-
genic thymocytes. Cell lysates from 5 3
106 transgenic (B6/PKB) or nontrans-
genic (B6) thymocytes were resolved by
10% SDS-PAGE and analyzed via West-
ern blotting. Blots were probed with an-
tibodies specific for Bcl-XL (top) and
Bcl-2 (bottom).
splenic T cells were alive (Fig. 6 B). This trend was ob-
served at up to 8 d of culture in vitro. Thus, expression of
PKB kinase activity can provide signals necessary for the
regulation of survival in mature T cells.
TCR-specific PKB Activation in Mature T Cells. Periph-
eral T lymphocytes remain in a quiescent state until their
antigen-specific TCR is triggered by peptide antigen
bound to MHC molecules on the surface of an APC. As li-
gation of the TCR initiates a series of signal transduction
events resulting in T cell proliferation and differentiation,
we examined whether PKB was activated in a TCR-
dependent fashion in naive T cells. As shown in Fig. 7 A,
activation of peripheral T cells with anti-CD3 alone or
anti-CD3 plus anti-CD28 led to a substantial increase in
PKB activation relative to untreated cells (NT). Activated
PKB was detected as early as 10 min after TCR ligation
and continued to remain high after 6 h (data not shown).
In addition, the failure of these stimulatory antibodies to
activate PKB in cells pretreated with the PI3K inhibitor
wortmannin (49) indicated that TCR-mediated activation
of PKB was dependent on PI3K activity. These results es-
tablish that PKB represents a physiologically relevant target
downstream of the TCR in primary T cells.
To investigate the functional consequences of PKB acti-
vation downstream of the TCR, we analyzed antigen-spe-
cific T cell proliferation using TCR transgenic mice. Sple-
nocytes from P14 TCR transgenic and P14/PKB double
transgenic animals were cultured in the presence of APCs
preincubated with p33 peptide, and proliferation was as-
sessed over time. While levels of proliferation remained
similar in both groups at 48 h, T cells expressing the gag-
PKB transgene displayed enhanced proliferation relative to
P14 control lymphocytes up to 120 h after activation (Fig.
7 B). Proliferation against an irrelevant control peptide (ad-
enovirus peptide AV) was ,4% of maximal proliferation
for all time points, regardless of gag-PKB transgene expres-
sion (data not shown). These data suggest that PKB activity
can alter antigen-specific T cell proliferation.1728 PKB Enhances T Cell Survival
Active PKB Leads to Increased Bcl-XL Levels but Not Phos-
phorylated BAD in Mature T Cells. Expression of the anti-
apoptotic proteins Bcl-2 and Bcl-XL is tightly regulated in
mature T cells. Bcl-2 expression is high in mature periph-
eral T cells and remains high after activation (50), whereas
Bcl-XL is upregulated only upon activation and has been
proposed to confer transient survival to activated T cells
(6). As transgenic thymocytes expressing gag-PKB upregu-
late Bcl-XL protein levels, we investigated whether PKB
activity could promote discordant expression of Bcl-XL in
mature T cells. Purified T lymphocytes from B6/PKB and
B6 control mice were lysed and Bcl-XL and Bcl-2 protein
levels were examined by Western blot (Fig. 8 A). Endoge-
nous levels of Bcl-XL were increased in transgenic mice
(B6/PKB) relative to negative littermate control mice (B6)
(Fig. 8, top), although not as dramatically as the levels ob-
served in thymocytes. There was no difference in Bcl-2
protein levels in the T cells of these mice (Fig. 8, middle),
suggesting that PKB does not affect Bcl-2 expression in
mature T cells. These results indicate that PKB influences
the level of Bcl-XL protein in mature T cells.
Recent studies have identified BAD, a proapoptotic
molecule of the Bcl-2 family, as being an important medi-
ator of cell death (15, 19, 20). PKB has been shown to
promote survival by directly phosphorylating BAD at Ser-
136, which favors the dissociation of BAD from Bcl-2/
Bcl-XL and permits its association with 14-3-3 (51). Thus,
PKB activity is hypothesized to antagonize BAD-mediated
repression of Bcl-2 and Bcl-XL. To determine the effect of
PKB kinase activity on BAD phosphorylation in T lym-
phocytes, we examined endogenous levels of BAD in gag-
PKB transgenic and nontransgenic T cells via Western blot
analysis (Fig. 8 A, bottom). BAD was detected in low
amounts in samples containing 2 3 107 T cells, consistent
with findings that BAD is not highly expressed in resting
T cells (15). Previous studies have indicated that hyper-
phosphorylation of BAD causes a decrease in mobility, and
that phosphorylated BAD can be detected as a protein
doublet via Western blot (51). Endogenous BAD was de-
tected as a single BAD protein band in both transgenic
(B6/PKB) and nontransgenic (B6) T cells (Fig. 8 A, bot-
Figure 6. PKB kinase activity protects
mature T cells from apoptosis-inducing
stimuli and spontaneous cell death in
vitro. (A) Transgenic gag-PKB T cells
are resistant to g irradiation and dexa-
methasone-induced apoptosis. Purified
CD41 and CD81 splenic T cells from
mice expressing the gag-PKB transgene
(B6/PKB5-4, h; or B6/PKB4-1, s) or lit-
termate controls (B6, j) were cultured
at 106 cells/ml after exposure to g radia-
tion or dexamethasone. Viability was de-
termined by trypan blue exclusion up to
48 h after treatment. Viability is ex-
pressed normalized to untreated T cells and in triplicate (6SEM). The data
are representative of four independent experiments. (B) PKB kinase activ-
ity enhances T cell survival. Purified CD41 and CD81 splenic T cells were
cultured at 106 cells/ml for 8 d at 378C. Cell viability was determined in
triplicate by trypan blue exclusion. The error bars represent the SEM ex-
pressed as cell numbers for each triplicate value. These data are representa-
tive of four independent experiments.
Figure 7. PKB is activated after TCR liga-
tion and enhances antigen-specific proliferation.
(A) PKB is activated in T cells in a TCR- and
PI3K-dependent fashion. Purified T cells (5 3
106) from C57BL/6J animals were left untreated
(NT) or stimulated with 10 mg/ml anti-CD3
antibody (aCD3), or anti-CD3 plus 2 mg/ml
anti-CD28 antibody for 2 h at 378C. W, pre-
treatment of cells with wortmannin (100 nM)
for 30 min before stimulation. PKB activity was
assayed by Western blot with antibodies specific
for PKB phosphorylated on Ser-473. Endoge-
nous PKB levels were measured using anti-PKB
antibodies. (B) P14 TCR transgenic thymocytes
expressing gag-PKB display enhanced antigen-specific proliferation over time. Splenocytes from P14 TCR transgenic (P14, d) or P14 TCR/gag-PKB
double transgenic (P14/PKB, s) animals were cultured for up to 5 d in the presence of APCs pre-pulsed with 1025 M p33 peptide, and pulsed with
[3H]thymidine at the indicated time points. To standardize for different experiments, scintillation counts obtained were normalized and expressed as a per-
centage of maximal proliferation (where maximal proliferation equals 100%). Mean proliferative values for each time point are indicated.1729 Jones et al.
tom). These data suggest that endogenous BAD is not nor-
mally phosphorylated in T cells, and that expression of an
activated allele of PKB does not lead to phosphorylation of
BAD in vivo.
PKB Activity Induces NF-kB Activation and IkB Degrada-
tion in Primary T Cells. Recent studies have shown that
PKB can activate the transcription factor NF-kB and pro-
mote survival (26–28). To determine whether PKB kinase
activity influences survival via NF-kB activity in T cells,
the following experiments were done. T cells from gag-
PKB transgenic (B6/PKB) or nontransgenic (B6) litter-
mates were treated with various stimuli and NF-kB activa-
tion was determined by gel mobility shift assays (Fig. 8 B).
Nuclear NF-kB was absent in untreated T cells (NT) from
both sets of mice, suggesting that expression of activated
PKB itself was insufficient to induce NF-kB activation
(Fig. 8 B). By contrast, nuclear levels of NF-kB site bind-
ing complexes were elevated dramatically in gag-PKB
transgenic T cells relative to controls when stimulated
with antibodies against CD3 and CD28, or PMA and ion-
omycin. Interestingly, significant levels of NF-kB activa-
tion were also detected when gag-PKB transgenic T cells
were treated with anti-CD28 antibodies alone. These data
indicate that PKB may enhance NF-kB–mediated gene
transcription driven by costimulatory signals through
CD28. More importantly, these data demonstrate that ac-
tivated PKB can facilitate the signaling pathway down-
stream of the TCR that leads to NF-kB activation.
NF-kB activity is normally inhibited in resting T cells
through sequestration by inhibitory proteins known as
IkBs. After T cell activation, IkB proteins are rapidly de-
graded through ubiquitin-mediated proteolysis, permitting
nuclear translocation of NF-kB and induction of gene tran-
scription (52). To investigate the mechanism of PKB-medi-
ated NF-kB activation in T cells, we examined the kinetics
of IkBa degradation via Western blot. T cells from trans-
genic (B6/PKB) and nontransgenic (B6) animals were
treated with cyclohexamide to prevent NF-kB–mediated
reexpression of IkB, and then stimulated with antibodies
specific for CD3 and CD28. As seen in Fig. 8 C, T cells ex-
pressing the gag-PKB transgene displayed accelerated loss of
IkB over time. Significant decreases in IkBa were observed
1 h after stimulation, with complete loss of IkBa protein at
2 h. By contrast, nontransgenic T cells maintained high lev-
els of IkBa at 1 h, and only began to show a decrease in
IkBa levels 2 h after activation. Collectively, these results
clearly demonstrate that PKB activity can increase NF-kB
activation in stimulated T cells, and that this regulation is
promoted at the checkpoint of IkBa degradation.
Discussion
PKB Inhibits T Cell Apoptosis: Association with Bcl-XL.
Recent work suggests that mammalian cells have devel-
oped several different apoptotic pathways that become acti-
vated in a cell type– and stimulus-dependent fashion. Our
studies demonstrate that one of the mechanisms by which
PKB antagonizes apoptosis involves the antiapoptotic mol-
ecule Bcl-XL. Previous studies have shown that Bcl-XL can
suppress different pathways of apoptotic death in T lym-
phocytes. Overexpression of Bcl-XL prevented dexametha-
sone- and g irradiation–induced death in thymocytes and T
cells (12, 13). Apoptotic signaling downstream of Fas can
be blocked in T cells by Bcl-XL in some models (6, 53, 54)
but not in other lymphoid cell lines (55–57), indicating that
the ability of Bcl-XL to block Fas-mediated cell death may
be restricted to certain cell types.
Figure 8. Mediators of survival in gag-PKB transgenic T cells. (A) Increased Bcl-XL levels, but no phosphorylated BAD, can be detected in gag-PKB
transgenic T cells. Cell lysates from transgenic (B6/PKB) or nontransgenic (B6) T cells were resolved by 10% SDS-PAGE and analyzed by Western blot.
Cell lysates from 5 3 106 thymocytes were probed with antibodies specific for Bcl-XL (top) and Bcl-2 (middle). Lysates from 2 3 107 thymocytes were
probed with antibodies against BAD (bottom). (B) PKB activity enhances NF-kB activation in T cells. Primary T cells isolated from LNs and spleens of
gag-PKB transgenic (B6/PKB) and control (B6) mice were left untreated (NT) or treated with the indicated stimuli for 4 h. Nuclear extracts were incu-
bated with a radiolabeled probe containing NF-kB binding sites, and NF-kB activation was determined using a gel mobility shift assay as described in
Materials and Methods. Bands corresponding to specific NF-kB–DNA complexes and nonspecific binding are indicated. (C) PKB activity enhances
IkBa degradation in response to TCR stimulation. T cells purified from gag-PKB transgenic (B6/PKB) or control (B6) mice were pretreated with 50
mg/ml cyclohexamide for 15 min, followed by stimulation with 10 mg/ml anti-CD3 and 2 mg/ml anti-CD28 antibodies for the times indicated. Whole
cell lysates were analyzed for IkBa protein levels by Western blot. The blots were stripped and probed with an antibody to b-actin to assess for equal
protein loading. This figure is representative of two independent experiments.1730 PKB Enhances T Cell Survival
We have observed that T lymphocytes expressing active
PKB exhibit significantly increased rates of survival after in-
duction of DNA damage (g irradiation) or steroid-induced
apoptosis (dexamethasone). Immature thymocytes express-
ing gag-PKB also show increased resistance to apoptosis
through stimulation of the Fas pathway. These data are
consistent with recent findings showing impaired Fas-
mediated apoptosis when COS7 cells are cotransfected with
gag-PKB and Fas constructs (42). Further evidence suggests
that the mechanism of PKB-mediated survival overlaps
with Bcl-XL pathways, as transgenic expression of both
gag-PKB and Bcl-XL enhances the survival of DP thy-
mocytes (48). Accordingly, increased levels of Bcl-XL pro-
tein were observed in gag-PKB transgenic mice. Collec-
tively, the gag-PKB mouse phenotype resembles that of
Bcl-XL transgenic mice (12, 13) and contrasts that of Bcl-X
gene–deficient mice (47, 48), suggesting that these two
molecules work in concert to oppose apoptosis in T cells.
Role of PKB during Thymocyte Selection. Current re-
search suggests the importance of two survival signals dur-
ing thymocyte development: a basal survival signal medi-
ated by Bcl-XL that maintains the CD41CD81 DP
thymocyte pool (47, 48), and a second signal induced upon
receipt of positive selection signals through the TCR that
results in the upregulation of Bcl-2 (45, 58). In our studies,
DP thymocytes expressing the gag-PKB transgene dis-
played a selective survival advantage over nontransgenic
controls. In this respect, activated PKB may enhance Bcl-
XL levels to ensure the survival of DP thymocytes that au-
dition for positive or negative selection. Although it is well
documented that PKB acts downstream of PI3K, the sig-
nals that activate PI3K during thymocyte development re-
main unknown.
Our studies have also shown that activated PKB is unable
to block antigen-induced negative selection. This is consis-
tent with past work that has demonstrated that Bcl-XL does
not prevent self-antigen–induced clonal deletion (13). To-
gether, these results demonstrate that PKB kinase activity
acts at the level of DP thymocyte survival, and that PI3K/
PKB signaling does not play a role in the apoptotic pathway
activated by TCR-mediated negative selection signals.
Mechanisms of PKB-mediated Survival: The Good and the
BAD. PKB may elicit its protective phenotype in T lym-
phocytes through a variety of mechanisms. We have dem-
onstrated a novel correlation between PKB activity and
Bcl-XL levels, and suggest that PKB promotes T cell sur-
vival through enhanced Bcl-XL expression. In other stud-
ies, Bcl-XL has been shown to interact with caspase 9 and
apoptotic protease-activating factor 1 (Apaf1), resulting in
the inhibition of caspase activation (59, 60). Increased lev-
els of Bcl-XL induced by PKB kinase activity may form in-
hibitory complexes with caspase 9, Apaf1, and cytochrome
c after apoptotic insult, delaying caspase activation and
slowing the progression of cell death in T cells. PKB-medi-
ated regulation of Bcl-XL may also antagonize the apop-
totic effects of Fas. Ligation of Fas by its cognate ligand or
through antibody stimulation results in the recruitment of
several proteins to form the death-inducing signaling com-
plex (61), and leads to caspase 8 activation (62). Bcl-XL has
been shown to act downstream of death-inducing signaling
complex formation and caspase 8 activation to impede Fas-
mediated death signals (54). This may be one way that PKB
acts to antagonize Fas-mediated death signals in thy-
mocytes.
PI3K activity has been shown to induce Bcl-XL expres-
sion at both the mRNA and protein levels in Baf-3 cells
(63), implying that the PI3K/PKB pathway may regulate
transcription of this antiapoptotic molecule. However,
PKB kinase activity does not regulate expression of Bcl-XL
at the transcriptional level in our transgenic mouse model.
Sequence analysis confirms that Bcl-XL lacks traditional
PKB phosphorylation consensus sites (RXRXXS/T) (64),
suggesting that PKB is unlikely to regulate Bcl-XL by direct
phosphorylation. However, relatively few downstream
substrates of PKB have been identified to date, giving rise
to the possibility of intermediary molecules that control
PKB-mediated Bcl-XL expression.
To date, one of the links between PKB and the cellular
apoptotic machinery has been through the ability of PKB to
phosphorylate the proapoptotic molecule BAD (19, 20).
Work by Mok et al. (15) indicates that transgenic overex-
pression of BAD in thymocytes renders them hypersensitive
towards dexamethasone, g radiation, and Fas-induced
death, possibly due to sequestration of endogenous Bcl-XL.
We show that BAD expression in normal T lymphocytes is
extremely low, and in contrast to other studies, our data
suggest that BAD is not phosphorylated in vivo by activated
PKB. This is in accordance with other models suggesting
that PKB-mediated phosphorylation of BAD is not the only
pathway by which PKB counters apoptotic death (65, 66).
BAD is not ubiquitously expressed, and cells that do not
express BAD are still protected from apoptosis via PKB sig-
naling (67). This appears to be the case in primary T cells;
past results show that BAD is not highly expressed in T cells
and induced only in response to apoptotic stimuli (15). The
effector molecules that promote survival downstream of
PKB signals are likely cell and stimulus specific. Taking
these findings into account, it is unlikely that BAD func-
tions as a relevant physiological substrate for PKB in T cells.
Integration of PKB Signaling with the NF-kB Pathway.
Another key pathway associated with cell survival is signal-
ing via the transcription factor NF-kB (68). In this study,
we provide the first evidence that PKB can be activated by
TCR cross-linking in mature T cells and that PKB influ-
ences NF-kB activation in primary T cells in response to
TCR stimulation. In T lymphocytes, NF-kB activation is
induced through engagement of the TCR (69). Mobility
shift assays performed using nuclear fractions from T cells
treated with anti-CD3 and anti-CD28 antibodies clearly
demonstrated that NF-kB activity was significantly in-
creased in T cells expressing gag-PKB, indicating that ac-
tive PKB mediates this effect in vivo. Interestingly, nuclear
translocation of NF-kB was induced in transgenic T cells
through CD28 stimulation alone. This evidence, coupled
with the fact that PKB is activated downstream of CD28 in
T lymphocytes (70), implicates PKB as a mediator of1731 Jones et al.
NF-kB activation downstream of CD28 costimulation.
Whereas CD3-mediated NF-kB activation is low in gag-
PKB transgenic T cells, stimulation with anti-CD3 and
anti-CD28 antibodies leads to a synergistic increase in NF-
kB nuclear translocation that is greater than that observed
with either treatment alone. Past studies indicate that co-
stimulatory signals can enhance TCR-mediated NF-kB ac-
tivation (71), and our data suggest that PKB plays a key role
in this process.
PKB-mediated regulation of NF-kB in T cells can be in-
fluenced by IkB degradation (52). The kinetics of IkBa
degradation were accelerated in gag-PKB transgenic mice
relative to controls, suggesting that PKB kinase activity in-
fluences NF-kB nuclear translocation by regulating levels
of IkB. Recent reports have suggested that PKB can phos-
phorylate one of the regulatory IkB kinases, IKKa,
through phosphorylation at a PKB phosphorylation con-
sensus sequence (Thr-23) located at its NH2 terminus (27).
Moreover, PKB-mediated NF-kB activity is impaired in
Jurkat cells cotransfected with PKB and kinase-deficient
IKK molecules (28). Thus, in our model, PKB may pro-
mote enhanced NF-kB transcriptional activity in response
to TCR triggering and costimulation through the activa-
tion of IKK. It is important to note that the expression of
active PKB does not lead to increased basal levels of NF-
kB activity, consistent with similar results observed in Jur-
kat cells (28). This points to a mechanism by which PKB
does not act alone, but requires the activation of other
molecules downstream of TCR-mediated signals to pro-
mote IKK activation, IkB degradation, and enhanced NF-
kB activity.
The ability of PKB to induce activation of NF-kB adds
an additional level of complexity to its function as a cyto-
protective agent. Our data, and those of others, suggest that
PKB may not simply function as an antagonist of proapop-
totic molecules; rather, PKB may promote cell survival, in-
cluding protection from apoptotic stimuli such as Fas ligand
or g-irradiation, through the induced expression of NF-
kB–regulated survival genes such as c-IAP1 (72), c-IAP2
(73), or Bfl-1/A1 (74). Previous work suggests that PI3K/
PKB regulates survival of Baf-3 cells via Bcl-XL (63). In-
deed, Bcl-XL has been identified as an NF-kB target gene,
but the exact role NF-kB plays in its regulation remains
controversial. NF-kB has been shown to prevent Fas-induced
death in B cells through the upregulation of Bcl-XL (75),
but has also been demonstrated to promote apoptosis in
thymocytes by downregulating Bcl-XL expression (76). Ex-
actly how PKB-mediated NF-kB activation functions in T
cells remains to be elucidated.
Concluding Remarks. Expression of active PKB in T
lymphocytes has provided key insights into the regulation
of T cell survival. It has provided an important link to a
previously undefined signaling pathway regulating Bcl-XL
expression. In addition, experiments with mature T cells
demonstrate that T cell activation via the TCR and costim-
ulatory molecules enhances T cell survival via PKB and
NF-kB. Our findings demonstrate that PKB-mediated sur-
vival is multifaceted; it is apparent that PKB signaling exerts
its antiapoptotic effects in T lymphocytes through a num-
ber of ways. However, more research is needed to fully un-
derstand the intricate regulation of T cell survival versus
apoptosis and the role that PKB plays in this process.
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